SCHEMBL2052383

SCHEMBL2052383

CCN1CCCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615128 0.84
SCHEMBL6631857 0.84 CXCR4 (0.48)
Tetradecane SCHEMBL27777921 0.83 CXCR4 (0.49)
Ammonia Solution, Strong SCHEMBL27788284 0.82
SCHEMBL28017309 0.82
SCHEMBL22871961 0.82 CXCR4 (0.52)
SCHEMBL27566558 0.81
SCHEMBL772696 0.80
SCHEMBL65385 0.80
SCHEMBL3635506 0.80 CXCR4 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 US disclosed
US-20240018122-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-18 US disclosed
US-20230322816-A1 PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF BEIJING SONGRUN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-10-12 US disclosed
US-20230322816-A1 PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF BEIJING SONGRUN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-10-12 US disclosed
WO-2023114428-A1 HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE Vir Biotechnology, Inc. (US) 2023-06-22 WO disclosed
WO-2021027943-A1 PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF 正大天晴药业集团南京顺欣制药有限公司 2021-02-18 WO disclosed
US-10913710-B2 Benzene disulfonamide for the treatment of cancer MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) 2021-02-09 US disclosed
US-20200377886-A1 EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY SAREPTA THERAPEUTICS, INC. (US) 2020-12-03 US disclosed
EP-3568391-B1 BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER MAX PLANCK GESELLSCHAFT (DE) 2020-11-11 EP disclosed
CN-110003172-A The amides containing carbazole, carbamates and ureas as cryptochrome regulator 同步制药公司 2019-07-12 CN disclosed
US-20090264612-A1 ALKOXYSILANE-TERMINATED PREPOLYMERS WACKER CHEMIE AG (DE) 2009-10-22 US disclosed
WO-2009038031-A1 BLOCK COPOLYMER AND PRODUCTION PROCESS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-26 WO disclosed
WO-2009038006-A1 RANDOM COPOLYMER AND PRODUCTION PROCESS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-26 WO disclosed
US-20080214755-A1 OLEFIN-DIENE COPOLYMER AND PROCESS FOR PRODUCING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-09-04 US disclosed
WO-2004015039-A1 NITROGEN COMPOUNDS FOR GAS ODORISATION SYMRISE GMBH & CO. KG (DE) 2004-02-19 WO disclosed
EP-0686143-B1 UNSATURATE AMINO COMPOUNDS FOR USE AS ANTICANCER AND ANTIPROTOZOIC AGENT CIBA GEIGY AG (CH) 1998-08-12 EP disclosed
US-5627215-A Unsaturate amino compounds for use as anticancer and antiprotozoic agent CIBA-GEIGY CORPORATION (US) 1997-05-06 US disclosed
CN-1121707-A Unsaturated amino compounds as anticancer and antiprotozoal agents CIBA GEIGY AG (CH) 1996-05-01 CN disclosed
EP-0686143-A1 UNSATURATE AMINO COMPOUNDS FOR USE AS ANTICANCER AND ANTIPROTOZOIC AGENT Novartis AG (CH) 1995-12-13 EP disclosed
WO-1995018091-A1 UNSATURATE AMINO COMPOUNDS FOR USE AS ANTICANCER AND ANTIPROTOZOIC AGENT CIBA-GEIGY AG (CH) 1995-07-06 WO disclosed